Cerebrospinal fluid (CSF) biomarkers are widely used in the diagnosis of dementia. Even though there is a causal correlation between apolipoprotein E (APOE) genotype and amyloid-beta (Ab), the determination of APOE is currently not supported by national or international guidelines. We compared parallel measured CSF biomarkers of two independent laboratories from 126 patients who underwent clinical dementia diagnostics regarding the APOE genotype. APOE e4 reduces Ab1-42 (Ab 42 ) and Ab 42 to Ab 1-40 ratio (Ab 42/40 ) but not total Tau or phospho-181 Tau CSF levels. Higher discordance rates were observed for Ab 42 and subsequently for Ab 42/40 in APOE e4 carriers compared with noncarriers, and the correlation between the two laboratories was significantly lower for Ab 42 in APOE e4 positive patients compared with patients without APOE e4. These observations demonstrate that the evaluation of CSF Ab biomarkers needs to be interpreted carefully in the clinical context. Different immunoassays, disparate cutoff values, and APOE should be respected.
Introduction
Biomarkers play a pivotal role in the clinical diagnosis of neurodegenerative disorders in particular for Alzheimer's disease (AD). AD biomarkers reflect the typical neuropathological hallmarks: hyperphosphorylated tangles and amyloid plaques. While increased phosphorylated tau (p181Tau) and total tau (tTau) indicate the tangle pathology in cerebrospinal fluid (CSF), amyloidbeta (Ab) 1-42 (Ab 42 ) levels and especially the decreased Ab 42 to amyloid-b 1-40 (Ab 40 ) ratio (Ab 42/40 ) embody the cerebral amyloid pathology that can be verified postmortem. The importance of these biomarkers in the clinical diagnosis of AD has been reflected in national (e.g., German) and international guidelines and recommendations (Dubois et al., 2007; McKhann et al., 2011; Cummings et al., 2013; Deuschl and Maier, 2016) . Novel research guidelines even more emphasize the significance of these biomarkers (Jack et al., 2018) .
We have recently shown that CSF biomarkers measured in different clinically validated and certified laboratories are interpreted discordantly in up to 31.5% of cases for Ab 42 (Vogelgsang et al., 2018) , whereas Ab 42/40 seems to be less prone to pre-analytical factors (Gervaise-Henry et al., 2017) . It is not clear whether these findings are caused by pre-analytical or analytical interferences.
Apolipoprotein E (APOE) e4 is the most prominent genetic risk factor for late-onset AD (Bertram and Tanzi, 2008) . Several studies have shown that APOE e4 is highly associated with amyloid pathology at any cognitive stage of AD (Mattsson et al., 2018) .
We aimed to analyze APOE e4 as an interfering factor that leads to inconsistent CSF biomarker results under routine clinical conditions. In addition, this study aims to describe the current difficulties in clinical interpretation of CSF Ab to make physicians aware of pitfalls. Therefore, CSF samples were sent and analyzed at two different, certified, clinical laboratories for biomarker determination.
Methods

Study Design
Within the biomaterial bank of the Department of Psychiatry and Psychotherapy of the University Medical Center Goettingen, we identified 126 samples from patients between 45 and 90 years where AD-relevant CSF biomarkers were measured in two independent, clinically certified laboratories during routine clinical diagnostic procedures, as described recently (Vogelgsang et al., 2018) . CSF biomarkers were measured according to the local standard operating procedures (SOPs), and both laboratories were not informed prior to the study to ensure routine procedures were maintained. No special effort was put in standardizing the SOPs. Biomarkers were measured using commercial and for in vitro diagnostic approved enzyme-linked immunosorbent assays (ELISAs). tTau (Fujirebio Cat# 81572, RRID:AB_2797379) and pTau (Fujirebio Cat# 81574, RRID:AB_2797380) were measured using ELISAs by Fujirebio (Ghent, Belgium), Ab 40 (IBL Cat# RE59651, RRID:AB_2797386) was measured using ELISAs by IBL International (Hamburg, Germany), and Ab 42 (IBL Cat# RE59661, RRID: AB_2797387 and Fujirebio Cat# 81576, RRID: AB_2797385) was measured using ELISAs by IBL and Fujirebio. CSF biomarkers were interpreted according to the corresponding cutoff values of the respective laboratory. Cutoff values were identified and adjusted during their routine validation procedures. At Center 1, cutoff values were 450 pg/ml for Ab 42 , 0.05 for the Ab 42/ 40 ratio, 450 pg/ml for tTau, and 61 pg/ml for pTau. At Center 2, cutoff values were 620 pg/ml for Ab 42 , 0.05 for the Ab 42/40 ratio, 320 pg/ml for tTau, and 50 pg/ml for pTau. Cutoff values were not adapted during the study.
A polymerase chain reaction (PCR) was performed to identify the APOE genotype and accordance for APOE e4 carriers (E2/E4, E3/E4, and E4/E4) and non APOE e4 carriers (E2/E2, E2/E3, E3/E3) were compared.
We compared each CSF biomarker independently and only included data from participants where the CSF biomarkers were significantly above or below cutoff, identified by AE10% of the respective cutoff value (borderline cutoff zone). Concordance was defined as an identical interpretation of biomarkers in both laboratories (either significantly above or below cutoff), whereas discordance was defined as dissimilar biomarker interpretations in the two corresponding laboratories (above the cutoff in one center and below the cutoff in the other center).
Sample Collection
CSF was collected by a lumbar puncture and stored in polypropylene tubes during the clinical diagnostic procedure. The lumbar puncture was performed in a seated position using a traumatic Quincke needle (BD Diagnostics, Franklin Lakes, NJ) or an atraumatic Sprotte cannula (Pajunk, Geislingen, Germany), according to the preference of the treating physician. The samples were sent immediately to two independent clinical laboratories for CSF biomarker measurements of Ab 42 , Ab 40 , Ab 42/40 , p181Tau, and tTau.
APOE Measurement
APOE genotyping was performed using a quantitative real-time PCR protocol as described previously (Calero et al., 2009) , with negative controls for all primer combinations and all PCR reactions run in duplicate. Measurements were carried out using a Stratagene MX3000P Real-Time PCR Cycler (Santa Clara, CA).
Statistics
Statistical analysis was performed using Prism Graph Pad 8 (RRID:SCR_002798). Age was compared using a student's t-test, and cohort differences for discordant CSF biomarkers and gender were analyzed using Fisher's exact test. Correlations were assessed by Spearman correlation and compared after calculating a Fisher r-to-z transformation.
Study Approval
All participants gave their informed consent for biomaterial and data collection prior to inclusion into this study. All data were pseudonymized. The study was approved by the ethics committee of the University Medical Center Goettingen (ethical vote 9/2/16). The study was conducted according to the Declaration of Helsinki.
Results
Study Cohort
In this study, 54 (42.9%) participants were APOE e4 carriers with a mean age of 70.4 AE 10.0 years. No APOE e4 allele was found in 72 (57.1%) participants with a mean age of 66.8 AE 10.3 years. There was a trend in distribution for age (p ¼ .0502) but not for gender (p ¼ .8564) between APOE e4 carriers and noncarriers. CSF biomarker accordance was compared after excluding cases within the borderline cutoff zone (AE10%) and age and gender were recalculated for each biomarker. No significant difference in age or gender was observed for any of the analyzed groups (Table 1) . To exclude patients with CSF Ab concentrations slightly below or above the respective cutoff value, we widened the borderline cutoff zone to AE25%. For Ab 42 , 12 APOE e4 carriers received discordant interpretations and 7 patients were interpreted concordantly. In APOE e4 noncarriers, only 5 of the 31 participants received discordant biomarker interpretations (p ¼ .0004; Figure 2 (a)). Noteworthy, this mismatch was not observed for Ab 42/40 . Regarding the latter Ab peptide ratio, only 3 of the 21 APOE e4 carriers and 1 of the 50 non APOE e4 carriers showed discordant results (p ¼ .0746; Figure 2 (b)).
CSF Biomarkers
CSF Ab biomarker concentrations were correlated between Center 1 and Center 2 for APOE e4 carriers and noncarriers separately. Samples with Ab concentrations above the upper limit of detection were excluded. Ab 42 correlated with r ¼ .5695 between Center 1 and Center 2 in APOE e4 carriers, whereas the correlation in non APOE e4 carriers was significantly higher r ¼ .7541 (z ¼ À1.801; p ¼ .036; Figure 3 (Table 2) . Ab 42 CSF levels were 756.3 AE 295.3 pg/ml for APOE e4 carriers and 1,087.0 AE 411.0 pg/ml for noncarriers at Center 1 (p < .0001) and 604.7 AE 324.9 pg/ml for APOE e4 carriers and 860.0 AE 447.6 pg/ml for noncarriers at Center 2 (p ¼ .0006). Ab 42/40 CSF levels were 0.0721 AE 0.0363 for APOE e4 carriers and 0.1021 AE 0.0396 for noncarriers at Center 1 (p < .0001) and 0.0473 AE 0.0189 for APOE e4 carriers and 0.0658 AE 0.0176 for noncarriers at Center 2 (p < .0001). Ab 40 CSF levels were 11,666 AE 3,747 pg/ml for APOE e4 carriers and 11,586 AE 4,528 pg/ml for noncarriers at Center 1 (p ¼ .9160) and 13,726 AE 6,099 pg/ml for APOE e4 carriers and 13,338 AE 6,047 pg/ml for noncarriers at Center 2 (p ¼ .7231; Table 2 ).
Discussion
In this study, we identified APOE e4 as a major factor leading to different Ab CSF biomarker interpretations in two independent laboratories. However, the APOE genotype did not affect Ab 40, tTau, or p181Tau CSF levels. The ELISAs used for tTau (Fujirebio), p181Tau (Fujirebio), and Ab 40 (IBL) were identical in both centers, whereas the ELISAs used for Ab 42 were different (IBL and Fujirebio) . This could be one reason for a higher discordance in Ab 42 compared with Ab 40, tTau, and p181Tau. However, this study reflects the real life in clinical dementia diagnostics, where physicians have limited impact on the used assays but need to rely on the best laboratory praxis in the corresponding centers. Even though it is not unexpected that different immunoassay show less concordance than identical immunoassays, the impact of APOE e4 on the accordance level is surprising. This effect was consistent even after excluding more some samples with CSF biomarkers close to the A further comparison between both immunoassays could improve the diagnostic accuracy in clinical laboratories; however, it is not trivial to determine the exact Ab levels in CSF and determine whether one immunoassay is superior to the other one.
Different functions of APOE have been described within the pathologic pathway of AD (reviewed in Bertram and Tanzi, 2008) . Besides assisting the transportation of Ab through the blood brain barrier, there is strong evidence that APOE interacts with Ab peptides (Naslund et al., 1995; Tiraboschi et al., 2004) and promotes conformational changes into b sheets (Wisniewski and Frangione, 1992) . As described by Strittmatter et al., APOE in general (Strittmatter et al., 1993a) , but APOE e4 even faster than APOE e3 (Strittmatter et al., 1993b) , binds to Ab peptides. This could affect the CSF biomarker measurements using enzyme-based immunoassays. We observed a reduced correlation between the ELISAs by IBL and Fujirebio in APOE e4 carriers compared with noncarriers, supporting the hypothesis that APOE e4 interacts with Ab 42 or one of the corresponding ELISAs.
Different studies have compared blood and CSF APOE levels. Wahrle et al. (2007) reported an agedependent effect on general APOE levels in CSF, whereas the dementia stage (as measured by the clinical dementia rating), the APOE genotype, gender, and race did not affect CSF APOE levels. Interestingly, CSF but not plasma APOE levels showed an APOE genotype independent association with Ab 42 concentrations in CSF (Cruchaga et al., 2012) .
According to the study by Mayeux et al. (1998) , without additional CSF or positron emission tomography (PET) biomarkers, APOE has a sensitivity of 65% and specificity of 68% for the detection of AD. Due to the limited diagnostic significance, national and international guidelines do not include APOE genotyping in the clinical diagnostics (Deuschl and Maier, 2016) . However, with the knowledge of a significant interference of APOE and Ab biomarker in the CSF, the determination of patients APOE genotype should be considered more important.
This study does not intend to explain any causal relation between APOE and Ab but aims to call attention to a critical interpretation of Ab CSF biomarkers in routine patient care and research. As CSF biomarkers are gaining importance in the etiological diagnosis of dementia, misinterpreted biomarkers have a significant impact on the clinical and therapeutic procedure (e.g., medication). Thus, false-negative CSF biomarker results could lead to insufficient treatment of AD patients.
Novel data suggest higher reproducibility CSF biomarkers using fully automated analyzers (Hansson et al., 2018) . However, further validation studies are needed to support the superiority of fully automated analyzers compared with classical ELISAs.
The determination of the APOE genotype could be a diagnostic benefit not only as a risk factor for AD but also as an interfering factor for CSF Ab biomarker measurements, which should be handled and interpreted carefully, in particular in APOE e4 positive patients. Due to the lacking gold standard (post mortem analysis), it is difficult to predict the superiority of one ELISA in this study. However, CSF Ab concentration slightly above or below the corresponding cutoff value should be questioned even more in APOE e4 positive patients. We recommend additional diagnostic procedures, for example, amyloid-PET if CSF biomarkers and clinical or neuropsychological examinations are conflicting. Moreover, this study strengthens the diagnostic use of Ab 42/40 to reduce insecure CSF biomarker interpretations.
Different immunoassays and cutoff points can render discordance between different laboratories. APOE e4 should be taken into account when applying round robin studies to harmonize cutoff values between different centers.
Strengths and Limitations of the Study
The major limitation of this study is the missing of harmonized SOPs, different infrastructures, and immunoassays. However, we did not address these aspects to outline the practical difficulties in the real-life clinical usage of biomarkers. The strength of this study is the naturalistic character of this analysis.
Summary
CSF biomarker misinterpretations are a widely known problem in clinical practice. This study shows that, besides different immunoassays and cutoff points, the APOE status contributes significantly to discordant CSF Ab biomarkers. APOE e4 increases the risk of misinterpreting CSF Ab 42 .
